What changed: Cancer of unknown primary (CUP)
Every dated change on the records linked to Cancer of unknown primary (CUP), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 3
- 2024GuidelineCancer of unknown primary (CUP)Guideline CUPISCO (Lancet 2024): Molecularly directed
Targeted therapy for actionable alterations (e.g. NTRK, BRAF V600E, HER2, ALK) and pembrolizumab for MSI-H/TMB-H; CUPISCO supports molecular-guided therapy after induction chemotherapy.
- 2024Trial resultCUPISCOCUPISCO reported
Median progression-free survival 6.
- 2024MilestoneComprehensive genomic profilingCUPISCO: molecularly guided therapy improves PFS (Lancet)
A milestone in how this cancer is treated.
2023 · 2
- 2023GuidelineCancer of unknown primary (CUP)Guideline ESMO CUP guideline 2023: Favourable subsets
Treat as the presumed primary: e.g. axillary node-only adenocarcinoma in women as breast cancer (mastectomy or axillary dissection + radiotherapy, systemic therapy); cervical node SCC with chemoradiation; peritoneal serous carcinoma as ovarian.
- 2023MilestoneCancer of unknown primary (CUP)ESMO guideline recommends comprehensive genomic profiling
A milestone in how this cancer is treated.